-
-
-
-
-
-
-
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
-
-
-
-
-
-
-
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
-
-
-
-
-
-
-
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases
-
-
-
-
-
-
-
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
-
-
-
1,197,259 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

